Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
CONCLUSION: Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel.
PMID: 26386102 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Arif SA, D'Souza J, Gil M, Gim S Tags: Am J Health Syst Pharm Source Type: research
More News: Aspirin | Bleeding | Cardiology | Cardiovascular | Clopidogrel | Drugs & Pharmacology | Health | Heart | Heart Attack | Hemorrhagic Stroke | Ischemic Stroke | Peripheral Vascular Disease (PVD) | Plavix | Stroke | Warnings